NO20005621L - Nye medikamentkombinasjoner - Google Patents

Nye medikamentkombinasjoner

Info

Publication number
NO20005621L
NO20005621L NO20005621A NO20005621A NO20005621L NO 20005621 L NO20005621 L NO 20005621L NO 20005621 A NO20005621 A NO 20005621A NO 20005621 A NO20005621 A NO 20005621A NO 20005621 L NO20005621 L NO 20005621L
Authority
NO
Norway
Prior art keywords
disorders
new drug
drug combinations
disorder
anxiety
Prior art date
Application number
NO20005621A
Other languages
English (en)
Other versions
NO20005621D0 (no
Inventor
Duncan Paul Taylor
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20005621L publication Critical patent/NO20005621L/no
Publication of NO20005621D0 publication Critical patent/NO20005621D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ny kombinasjonsbehandling av selektive, noradrenalinreopptaksinhibitorer (NARI) og spesielt reboxetin og pindolol, for å frembringe rask lindring for pasienter som lider av depresjon, generell angst, "attention deficit hyperactivity disorder (ADHD), angstforstyrrelser slik som "obsessive compulsive disorders " (OCD), paniske forstyrrelser (PD), sosiale fobier (SD) og liknende.
NO20005621A 1998-05-08 2000-11-07 Nye medikamentkombinasjoner NO20005621D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8486098P 1998-05-08 1998-05-08
PCT/US1999/006523 WO1999058130A1 (en) 1998-05-08 1999-04-14 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Publications (2)

Publication Number Publication Date
NO20005621L true NO20005621L (no) 2000-11-07
NO20005621D0 NO20005621D0 (no) 2000-11-07

Family

ID=22187677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005621A NO20005621D0 (no) 1998-05-08 2000-11-07 Nye medikamentkombinasjoner

Country Status (22)

Country Link
EP (1) EP1075264B1 (no)
JP (1) JP2002514601A (no)
KR (1) KR20010052319A (no)
CN (1) CN1300217A (no)
AT (1) ATE283694T1 (no)
AU (1) AU764579B2 (no)
BR (1) BR9909559A (no)
CA (1) CA2326105A1 (no)
DE (1) DE69922367T2 (no)
EA (1) EA003469B1 (no)
ES (1) ES2232128T3 (no)
HU (1) HUP0101341A3 (no)
IL (1) IL139211A0 (no)
NO (1) NO20005621D0 (no)
NZ (1) NZ508035A (no)
PL (1) PL345351A1 (no)
PT (1) PT1075264E (no)
SI (1) SI1075264T1 (no)
SK (1) SK14502000A3 (no)
TR (1) TR200003262T2 (no)
WO (1) WO1999058130A1 (no)
ZA (1) ZA200005301B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286669B6 (sk) 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu periférnej neuropatie
EP1459750B1 (en) * 1999-07-01 2005-06-01 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating fibromyalgia and other somatoform disorders
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
ATE376419T1 (de) 2002-12-27 2007-11-15 Otsuka Pharma Co Ltd Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
JP2012526832A (ja) * 2009-05-13 2012-11-01 スノビオン プハルマセウトイカルス インコーポレイテッド トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
AU6776196A (en) * 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response

Also Published As

Publication number Publication date
PT1075264E (pt) 2005-01-31
SK14502000A3 (sk) 2001-05-10
EA003469B1 (ru) 2003-06-26
KR20010052319A (ko) 2001-06-25
CN1300217A (zh) 2001-06-20
NZ508035A (en) 2004-02-27
JP2002514601A (ja) 2002-05-21
AU764579B2 (en) 2003-08-21
ZA200005301B (en) 2001-10-01
BR9909559A (pt) 2000-12-19
EP1075264B1 (en) 2004-12-01
IL139211A0 (en) 2001-11-25
CA2326105A1 (en) 1999-11-18
HUP0101341A2 (hu) 2001-08-28
SI1075264T1 (en) 2005-06-30
DE69922367D1 (de) 2005-01-05
PL345351A1 (en) 2001-12-17
ATE283694T1 (de) 2004-12-15
TR200003262T2 (tr) 2001-03-21
HUP0101341A3 (en) 2006-07-28
WO1999058130A1 (en) 1999-11-18
DE69922367T2 (de) 2005-12-22
AU3546099A (en) 1999-11-29
ES2232128T3 (es) 2005-05-16
NO20005621D0 (no) 2000-11-07
EP1075264A1 (en) 2001-02-14
EA200001162A1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
Shulman et al. Current place of monoamine oxidase inhibitors in the treatment of depression
Ozyalcin et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine
Brunello et al. Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment
CY1124111T1 (el) Παραγοντες ρυθμισης γλουταμικου στην αντιμετωπιση ψυχικων διαταραχων
RS27704A (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
NO20100333L (no) Behandling av nevrotiske forstyrrelser
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
AP2002002481A0 (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors.
NO20052420L (no) Farmakologisk behandling av sovnapn±.
NO20005621L (no) Nye medikamentkombinasjoner
ATE447403T1 (de) Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
TNSN05131A1 (en) New synergistic combination comprising roflumilast and formoterol
Sood et al. Diagnosis and treatment of pathologic gambling
HUP0402619A2 (hu) Norepinefrin re-uptake inhibitorok alkalmazása a megértési nehézségek kezelésére használható gyógyszer előállítására
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
WO2002040006A3 (en) Treatment of anxiety disorders
HUP0101748A2 (hu) Reboxetin alkalmazása idegrendszeri zavarok kezelésére szolgáló gyógyszerkészítmények előállítására
NO20085172L (no) 3-(1h-indol-3-yl)indan-1-ylaminderivater for behandlingen av depresjon og angst
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
PT1282414E (pt) Compostos derivados de felbamato para o tratamento da dor neuropatica
NO20061427L (no) Kombinasjonen av en serotonin-reoppttaksinhibitor og amoxapin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application